Finally, the potential use of novel drugs such as PHD inhibitors and SGLT2 inhibitors, stabilizing HIF and inducing EPO production also question the dogma of the detrimental effect of this pathway during renal disease (Fig. 1). The gene discussed is EPO; the disease is kidney disorder.